Baxter International announced it will form a R&D center in Cambridge, Massachusetts for its new biopharmaceutical company, Baxalta.
Baxter International announced on Sept. 29, 2014 that it will form a R&D center in Cambridge, Massachusetts for its new independent global biopharmaceutical company, Baxalta. The company expects to enhance its innovation pipeline—focused on hematology, immunology, gene therapy, and biosimilars—allowing them to improve patient care.
Cambridge was chosen for the new R&D space because of the rich biotech community present in the area. Cambridge launched an initiative in May of 2014, along with four other cities in Massachusetts, called the Life Sciences Corridor. This initiative encourages the growth of labor forces, research universities and hospitals, R&D districts, and venture capital resources by offering mass transit connections between the five cities (Cambridge, Boston, Quincy, Somerville, and Braintree) focused on the life sciences sector.
Corporate Headquarters for the company will remain in Illinois with R&D operations remaining active in Vienna, Austria. Some individuals working in R&D positions in California and Europe will relocate to the new R&D center in Cambridge, where the company expects approximately 400 employees will be situated.
Baxalta is expected to become a separate entity in 2015, however Baxter anticipates that the first phase of the 200,000-sq-ft leased space will be open by the end of 2014.
Sources:
Baxter International Cambridge
VERAXA and Voyager to Create Combined Business for Advancing Pipeline of Next-Gen Cancer Therapies
April 23rd 2025The proposed business combination would create a publicly traded, clinical-stage biopharmaceutical company that will focus on developing a pipeline of next-generation cancer therapies.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
Tokyo University of Science Research Team Explores Improved Delivery of Antisense Oligonucleotides
April 18th 2025Using cholesterol-modified oligonucleotides, the research team aims to improve the delivery of antisense nucleotide-based therapies for treating neurodegenerative diseases and brain cancers.